International Clinical Trial: JH013 Injection in Patients With Primary Sjogren's Syndrome

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07818694) titled 'JH013 Injection in Patients With Primary Sjogren's Syndrome' on Sept. 3.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Biotech Pharmaceutical Co., Ltd.

Condition: Primary Sjogren's Syndrome (pSS)

Intervention: Biological: JH013 injection

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: September 30, 2026

Target Sample Size: 54

To know more, visit https://clinicaltrials.gov/study/NCT07818694

Disclaimer: Curated by HT Syndication....